Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Exploratory, Eight-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause

Next Previous
Trial Profile

A Phase 2, Exploratory, Eight-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Mesafem (Paroxetine Mesylate) Capsules in the Treatment of Vasomotor Symptoms Associated With Menopause

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 May 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paroxetine (Primary)
  • Indications Hot flashes; Menopausal syndrome; Vasomotor symptoms
  • Focus Therapeutic Use
  • Sponsors Noven Pharmaceuticals

Most Recent Events

  • 18 May 2012 Results presented at the 60th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.
  • 14 Jul 2009 Positive top-line results reported in Noven pharmaceuticals media release.
  • 14 Jul 2009 Planned number of patients changed from 110 to 102, according to Noven Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top